Guardant Health and Zephyr AI announced a strategic partnership to combine Guardant’s multimodal molecular datasets with Zephyr’s AI analytics to accelerate discovery of genomic biomarkers for targeted oncology therapies. The collaboration will integrate with Guardant’s Infinity AI suite and aims to improve predictions of therapy response for biopharma partners. Guardant co‑CEO Helmy Eltoukhy highlighted data as central to precision oncology and framed the partnership as a step toward faster drug development and better patient selection. Financial terms were not disclosed; initial activity will focus on R&D‑stage biomarker generation and validation. The deal is part of growing industry momentum to fuse clinical‑grade sequencing with advanced machine learning to de‑risk target selection and enrich clinical trials.